IL6 and COVID-19: As early as February of 2020, the anti-IL-6 receptor (IL-6R) blocking antibody tocilizumab was assessed for therapeutic efficacy in a randomised control trial in China [70] to counter the putative COVID-19-induced CSS, where IL-6 is thought to play a key role.